BlackBarn Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

BlackBarn Capital Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12M	Hold	2,500,000	–	–	1.01%	20
2026 Q1	$11.3M	Buy	2,500,000 +650,000	+35%	+$2.84M	0.91%	17
2025 Q4	$8.9M	Sell	1,850,000 -150,000	-8%	-$674K	0.59%	15
2025 Q3	$9.08M	Sell	2,000,000 -603,521	-23%	-$2.22M	0.65%	18
2025 Q2	$8.04M	Buy	2,603,521 +261,650	+11%	+$869K	0.46%	18
2025 Q1	$8.17M	Hold	2,341,871	–	–	0.52%	16
2024 Q4	$7.66M	Buy	2,341,871 +270,971	+13%	+$997K	0.42%	14
2024 Q3	$7.97M	Hold	2,070,900	–	–	1.05%	14
2024 Q2	$6.4M	Hold	2,070,900	–	–	0.57%	19
2024 Q1	$5.34M	Buy	+2,070,900	New	+$5.36M	3.02%	14

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackBarn Capital Partners's ABUS Position: Q2 2026 in Review

BlackBarn Capital Partners held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 2,500,000 shares worth $12M. The position accounts for 1.01% of the portfolio, ranked #20.

BlackBarn Capital Partners first reported a position in ABUS in Q1 2024 and has held it in 10 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

BlackBarn Capital Partners held 2,500,000 shares of Arbutus Biopharma worth $12M as of Q2 2026.
BlackBarn Capital Partners left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up 1.01% of BlackBarn Capital Partners's portfolio in Q2 2026, its #20 holding.
BlackBarn Capital Partners first reported a position in Arbutus Biopharma in Q1 2024 and has held it in 10 quarters since.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on BlackBarn Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.